ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Size-Dependent Neutralization Efficacy of Nanodecoys Against SARS-CoV-2 Mimics in Mammalian Cell Infection Models.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nanodecoys that competitively inhibit viral entry represent a promising antiviral strategy, yet the influence of their physical properties on performance remains underexplored. In this work, we systematically investigate the size-dependent antiviral activity of ACE2-conjugated nanodecoys against a safe SARS-CoV-2 mimic. Our results demonstrate that the inhibition of mimic cellular uptake is highly size-dependent. The 10 nm nanodecoys exhibited the most potent neutralization, followed by the comparable 5 and 20 nm, while the 50 and 100 nm nanodecoys demonstrated similar, lower efficacies. This work identifies nanodecoy size as a critical design principle, providing a rational framework for engineering high-performance antiviral nanotherapeutics to combat SARS-CoV-2 and other viral pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.